NRX Pharmaceuticals Inc (NRXP) - Total Liabilities
Based on the latest financial reports, NRX Pharmaceuticals Inc (NRXP) has total liabilities worth $40.75 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NRXP cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
NRX Pharmaceuticals Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how NRX Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of NRX Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Top Systems-L
TA:TOPS
|
Israel | ILA234.43 Million |
|
Dutaland Bhd
KLSE:3948
|
Malaysia | RM89.33 Million |
|
JLS Co.Ltd
KQ:040420
|
Korea | ₩19.77 Billion |
|
Herige SA
PA:ALHRG
|
France | €191.51 Million |
|
K Wave Media Ltd.
NASDAQ:KWM
|
USA | $101.67 Million |
|
Wintao Communications Co. Ltd
SHE:301139
|
China | CN¥1.42 Billion |
|
Grupo Mexicano de Desarrollo S.A.B
MX:GMD
|
Mexico | MX$3.45 Billion |
|
Lowell Resources Fund
AU:LRT
|
Australia | AU$2.41 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down NRX Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See NRX Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NRX Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NRX Pharmaceuticals Inc (2017–2024)
The table below shows the annual total liabilities of NRX Pharmaceuticals Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $26.87 Million | +41.09% |
| 2023-12-31 | $19.05 Million | +3.48% |
| 2022-12-31 | $18.41 Million | +54.38% |
| 2021-12-31 | $11.92 Million | -74.48% |
| 2020-12-31 | $46.71 Million | +1714.62% |
| 2019-12-31 | $2.57 Million | +104.72% |
| 2018-12-31 | $1.26 Million | +1249.57% |
| 2017-12-31 | $93.17K | -- |
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more